STOCK TITAN
  1. Home
  2. Sec-filings
  3. DARE
  4. [8-K] Dare Bioscience, Inc. Reports Material Event

Daré Bioscience (NASDAQ: DARE) furnishes July 24 investor deck

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Daré Bioscience, Inc. furnished a corporate presentation dated July 24, 2026 as Exhibit 99.1 under Regulation FD. The company intends to use this presentation in meetings with securities market participants and others beginning July 24, 2026.

Daré Bioscience plans to make the presentation available in the Investors section of its website, on the page titled “Presentations, Events & Webcasts” under “Presentations.” The related information is being furnished, not deemed “filed” for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into other Exchange Act or Securities Act filings except where specifically referenced.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Corporate presentation date July 24, 2026 Date of Daré Bioscience corporate presentation furnished as Exhibit 99.1
Commission File Number 001-36395 Company’s Commission File Number under the Exchange Act
Exhibit 99.1 99.1 Exhibit number for Daré Bioscience corporate presentation
Exhibit 104 104 Exhibit number for Cover Page Interactive Data File
Regulation FD regulatory
"Item 7.01 Regulation FD Disclosure."
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
incorporated by reference regulatory
"which is incorporated herein by reference."
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What did Daré Bioscience (DARE) disclose on July 24, 2026?
Daré Bioscience furnished a corporate presentation dated July 24, 2026 as Exhibit 99.1 under Regulation FD. The company plans to use this presentation in meetings with securities market participants and others beginning on that same date.

How will investors be able to access Daré Bioscience’s July 24, 2026 presentation (DARE)?
Daré Bioscience plans to post the July 24, 2026 corporate presentation in the Investors section of its website. It will appear on the “Presentations, Events & Webcasts” page under the heading “Presentations.”

Is the Daré Bioscience (DARE) July 24, 2026 presentation considered filed with the SEC?
No. The Item 7.01 information and Exhibit 99.1 are being furnished and are not deemed “filed” for Section 18 of the Exchange Act, nor incorporated by reference into other Exchange Act or Securities Act filings, except where specifically referenced.

Under which SEC item was Daré Bioscience’s (DARE) investor presentation reported?
The corporate presentation dated July 24, 2026 was disclosed under Item 7.01, Regulation FD Disclosure. This item is used to provide broad, non-selective public access to information shared with securities market participants.

What exhibits did Daré Bioscience (DARE) include with this Form 8-K?
Daré Bioscience listed Exhibit 99.1, its corporate presentation dated July 24, 2026, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.
false 0001401914 0001401914 2026-07-24 2026-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 24, 2026

 

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36395   20-4139823

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

 

Registrant’s telephone number, including area code: (858) 926-7655

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock   DARE   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

Furnished as Exhibit 99.1 to this report is a copy of a corporate presentation of Daré Bioscience, Inc. (“Daré” or the “Company”) dated July 24, 2026, which is incorporated herein by reference. The Company intends to use the presentation and its contents in various meetings with securities market participants and others, commencing on July 24, 2026.

 

The Company plans to make a copy of the presentation available in the “Investors” section of its website (https://ir.darebioscience.com), on the page titled “Presentations, Events & Webcasts,” under the heading “Presentations.” Information contained in, or that can be accessed through, the Company’s website or any other website referenced in the presentation is not incorporated by reference into this report.

 

The information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Daré Bioscience corporate presentation, dated July 24, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  DARÉ BIOSCIENCE, INC.
   
Dated: July 24, 2026 By: /s/ Sabrina Martucci Johnson
  Name: Sabrina Martucci Johnson
  Title: President and Chief Executive Officer

 

-3-

 

 

Exhibit 99.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

43 documents

Press Releases

Other Documents